QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 guggenheim-reiterates-buy-on-rezolute-maintains-15-price-target

Guggenheim analyst Debjit Chattopadhyay reiterates Rezolute (NASDAQ:RZLT) with a Buy and maintains $15 price target.

 maxim-group-maintains-buy-on-rezolute-raises-price-target-to-20

Maxim Group analyst Jason McCarthy maintains Rezolute (NASDAQ:RZLT) with a Buy and raises the price target from $15 to $20.

 btig-reiterates-buy-on-rezolute-maintains-17-price-target

BTIG analyst Julian Harrison reiterates Rezolute (NASDAQ:RZLT) with a Buy and maintains $17 price target.

 rezolute-q4-eps-026-misses-022-estimate

Rezolute (NASDAQ:RZLT) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.22) by...

 hc-wainwright--co-reiterates-buy-on-rezolute-maintains-14-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Rezolute (NASDAQ:RZLT) with a Buy and maintains $14 price target.

 rezolute-files-prospectus-to-resale-of-13m-shares-of-common-stock-by-selling-stockholders

-SEC Filing

 rezolute-to-present-late-breaking-phase-3-data-on-rare-hypoglycemia-treatment-at-endo-2025

Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treati...

 rezolute-q3-eps-027-misses-023-estimate

Rezolute (NASDAQ:RZLT) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.23) by...

 rezolute-fda-grants-breakthrough-therapy-designation-to-investigational-therapy-ersodetug-for-treatment-of-hypoglycemia-caused-by-tumor-hi

Registrational study in patients with tumor hyperinsulinism (HI) expected to commence mid-yearDesignation underscores need for ...

 hc-wainwright--co-reiterates-buy-on-rezolute-maintains-14-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Rezolute (NASDAQ:RZLT) with a Buy and maintains $14 price target.

 rezolute-thrilled-with-positive-review-of-genetic-disorder-trial-expects-topline-results-in-december

Rezolute advances HI drug trial after DMC review and secures $90 million in funding through stock offering to support development.

 rezolute-announces-pricing-of-offering-of-90m-at-335-per-share-of-common-stock-and-pre-funded-warrants

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late...

 rezolute-announces-the-data-monitoring-committees-recommendation-to-continue-phase-3-sunrize-study-as-planned-in-patients-with-congenital-hi-without-an-increase-in-the-study-sample-size

Independent Data Monitoring Committee (the "DMC") recommends continuation of sunRIZE trial as planned with no need to i...

 hc-wainwright--co-reiterates-buy-on-rezolute-maintains-14-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Rezolute (NASDAQ:RZLT) with a Buy and maintains $14 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION